Eisai Receives "IR Grand Prix Award"

Nov, 14 2018 13:30 JST

Source: Eisai

TOKYO, Nov, 14 2018 - (JCN Newswire) - Eisai Co., Ltd. has announced that it received the "IR Grand Prix Award" at the IR Award 2018 held by the Japan Investor Relations Association (JIRA). This marks the second time that Eisai has received the IR Grand Prix Award following 2006. Including the receipt of Best IR Awards in 2004, 2005, 2009 and 2012, this is the 6th time Eisai has received an IR Award, and Eisai is the first pharmaceutical company to receive two IR Grand Prix Awards.

The IR Award (Committee Chairman: Tetsuo Kitagawa, Professor of International Management, Aoyama Gakuin University Graduate School) is designed to recognize companies which have been highly accredited in the investment community for their understanding and promotion of IR activities, and this year marks the 23rd year since the start of the IR Awards. 299 companies applied for the IR Award 2018, and after surveys and screenings by select committee members, Eisai was the sole company selected for the IR Grand Prix Award this year.

The reasons for Eisai's selection are as follows:
"Eisai is proactively disclosing information and constantly raising the level of disclosure. For many years, top management has been engaged in dialogue with investors, candidly discussing the company's longer-term vision and management issues. Eisai's CFO and IR Department have been enhancing the presentation of balance sheet management and disclosure of non-financial information ahead of other companies. In terms of ESG-related efforts, Eisai not only discloses information but also holds meetings with presentations by outside directors and meetings to explain its integrated report. The company's timeliness and fairness in disclosure is highly regarded, evidenced by its timely disclosure of information that may affect operating performance and prompt holding of briefings on such matters."

Furthermore, in celebration of the 25th year since the establishment of the JIRA, as part of the "JIRA 25th Anniversary Commemorative Award" which seeks to specially recognize companies which have continued IR activities over the long term and have produced outstanding achievements in appropriate information disclosure and constructive dialogue with investors and shareholders, Eisai was selected as both a "Company with Greatest Improvement in IR" and as a "Company with Best Continual Efforts in IR." For further details, please visit the JIRA website: https://www.jira.or.jp/english/.

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Together with strengthening its ESG initiatives in order to realize this corporate philosophy, Eisai respects the rights of shareholders and investors, ensures fairness and transparency in management, and works on its IR activities to aid the enhancement of corporate value.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

Furthermore, we invest and participate in several partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com

Contact:

Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: BioTech

Related Press Release

Eisai Submits Application in Europe Seeking Approval for Fycompa as Treatment for Pediatric Patients With Epilepsy

February 13 2019 08:29 JST

Eisai and Purdue Pharma Present Efficacy and Safety Data from Second Pivotal Phase 3 Study

February 04 2019 11:57 JST

Eisai's Supplementary New Drug Application Submitted In Japan for Fycompa

January 30 2019 15:22 JST

Eisai Listed as a Global 100 Most Sustainable Corporation for the Fourth Time

January 22 2019 16:54 JST

Eisai's Notification Regarding Results of Voluntary Retirement Program

January 18 2019 13:33 JST

Eisai to Present Results of Post-Hoc Analyses of Lenvima (Lenvatinib) Phase III Reflect Study in Hepatocellular Carcinoma at 2019 Gastrointestinal Cancers Symposium

January 15 2019 13:31 JST

Eisai's New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United States

January 15 2019 13:23 JST

Eisai's Etak Antimicrobial Spray Alpha Wins Nikkei Business Daily Awards for Superiority at the 2018 Nikkei Superior Products and Services Awards

January 04 2019 11:18 JST

Eisai's New Drug Application for Perampanel Designated for Priority Review by China National Medical Products Administration

January 04 2019 08:39 JST

Eisai: Bristol-Myers Squibb and H3 Biomedicine Announce Research Collaboration to Advance Novel Therapeutics Leveraging H3's RNA Splicing Platform

December 18 2018 10:38 JST

More Press release >>

Latest Press Release

NEC Supports the Safety of Automated Driving with Demonstration of Adaptive Network Control Technology

Feb 21, 2019 10:29 JST

NEC Wins Multiple iF DESIGN AWARDs
Feb 21, 2019 10:06 JST

NEC Launches NEC 5G Vertical Business Platform

Feb 20, 2019 16:43 JST

Prince of Songkla University (Thailand) and Hitachi Jointly Develop Sentiment Analysis Engine for Thai Language
Feb 20, 2019 16:03 JST

MHI Thermal Systems Establishes Centrifugal Chiller, Air-Conditioner and Heat Pump Water Heater Construction and Engineering Company in China
Feb 20, 2019 11:21 JST

Honda Announces Global Automobile Manufacturing Restructure
Feb 19, 2019 17:21 JST

Summary of Honda CEO Speech on Organizational Changes
Feb 19, 2019 17:04 JST

NEC Passes the First ETSI Millimetre Wave Transmission (mWT) Plugtests Event
Feb 19, 2019 16:30 JST

NEC Withdraws from a Segment of Ratings Coverage
Feb 19, 2019 15:45 JST

Mitsubishi Corporation: Gas4Sea Partners and Equinor Signed an LNG Bunkering Agreement
Feb 19, 2019 15:31 JST

Mitsubishi Heavy Industries Signs LOI to Join Charter of Trust for Cybersecurity

Feb 19, 2019 13:40 JST

MHPS Receives Order from Chinese Steelmaker for M701S(DA)X Gas Turbine and Other Key Components for Thermal Power Generation
Feb 19, 2019 12:02 JST

NEC: Full-Fledged Deployment of "Trifacta Wrangler Enterprise" to Establish Environment for Utilization of Big Data

Feb 19, 2019 09:07 JST

NEC to Build Submarine Cable System for Okinawa Cellular Telephone Company

Feb 19, 2019 08:30 JST

DOCOMO Ranked World's Top Mobile Operator in 5G SEP Applications and Contributions to 5G Standard

Feb 18, 2019 18:25 JST

DOCOMO to Provide Photo Album Service on OEM Basis to FET in Taiwan

Feb 18, 2019 18:07 JST

Mitsubishi Motors: Alliance Ventures Invests in PowerShare to Advance Charging Solutions and Services for Electric Vehicles
Feb 18, 2019 17:41 JST

DENSO Announces New Executive Structure and Management Changes
Feb 18, 2019 16:02 JST

Toyota's New Hiace Series for Overseas Markets Debuts in Philippines

Feb 18, 2019 15:03 JST

Fujitsu Receives Order for Massively Parallel Supercomputer System from The University of Tokyo

Feb 18, 2019 11:24 JST

More Latest Release >>